In this video interview with SOHO Insider, Dr. Mead, a professor of hematology at the University of Oxford, presents interim results from the phase 1 PROMise trial at the 67th American Society of Hematology Annual Meeting and Exposition.
Dr. Mead discusses the trial’s goals for combining the BET inhibitor OPN-2853 with ruxolitinib in patients with myelofibrosis who had an inadequate response to ruxolitinib alone. He also speaks about the study’s dose-finding design, early signs of tolerability and efficacy, and the combination’s potential for further development.
Reference
Mead A, Psaila B, Boucher R. Interim analysis of PROMise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis experiencing an inadequate response to ruxolitinib. Abstract #3794. Presented at the 67th ASH Annual Meeting and Exposition. December 6–9, 2025; Orlando, Florida.
